Literature DB >> 27074843

Vaginal Health During Breast Cancer Treatment.

Sandy J Falk1, Sharon Bober2.   

Abstract

There are increasing numbers of breast cancer survivors. Chemotherapy or endocrine therapy result in effects on vaginal health that may affect quality of life. These effects may impact sexual function, daily comfort, or the ability to perform a pelvic examination. Vulvovaginal atrophy, or genitourinary syndrome of menopause, may be treated with nonhormonal or hormonal measures. Breast cancer survivors who are menopausal and/or on endocrine therapy should be screened for issues with vaginal health and counseled about treatment options.

Entities:  

Keywords:  Breast cancer; Conjugated equine estrogens; Dyspareunia; Genitourinary syndrome of menopause; Menopause; Premature ovarian failure; Vaginal dryness; Vaginal estrogen therapy; Vaginal lubricants; Vulvovaginal atrophy

Mesh:

Substances:

Year:  2016        PMID: 27074843     DOI: 10.1007/s11912-016-0517-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  46 in total

1.  Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.

Authors:  Angela M Gordon; Shelley Hurwitz; Charles L Shapiro; Meryl S LeBoff
Journal:  Menopause       Date:  2011-11       Impact factor: 2.953

2.  Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy.

Authors:  S Salvatore; R E Nappi; M Parma; R Chionna; F Lagona; N Zerbinati; S Ferrero; M Origoni; M Candiani; U Leone Roberti Maggiore
Journal:  Climacteric       Date:  2014-12-16       Impact factor: 3.005

3.  The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause.

Authors:  Maria Le Donne; Carmela Caruso; Alfredo Mancuso; Gregorio Costa; Raffaella Iemmo; Giovanni Pizzimenti; Vittorio Cavallari
Journal:  Arch Gynecol Obstet       Date:  2010-06-25       Impact factor: 2.344

4.  Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice.

Authors:  Young H Ju; Daniel R Doerge; Kimberly F Allred; Clinton D Allred; William G Helferich
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

5.  Effect of tamoxifen on sexual functioning in patients with breast cancer.

Authors:  J E Mortimer; L Boucher; J Baty; D L Knapp; E Ryan; J H Rowland
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

6.  Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment.

Authors:  Nicola Zerbinati; Maurizio Serati; Massimo Origoni; Massimo Candiani; Tommaso Iannitti; Stefano Salvatore; Francesco Marotta; Alberto Calligaro
Journal:  Lasers Med Sci       Date:  2014-11-20       Impact factor: 3.161

Review 7.  Ospemifene, vulvovaginal atrophy, and breast cancer.

Authors:  Gregory T Wurz; Lin H Soe; Michael W DeGregorio
Journal:  Maturitas       Date:  2013-01-16       Impact factor: 4.342

Review 8.  The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions.

Authors:  Kelly Mok; Ilona Juraskova; Michael Friedlander
Journal:  Breast       Date:  2008-05-14       Impact factor: 4.380

9.  Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.

Authors:  Cynthia A Stuenkel; Susan R Davis; Anne Gompel; Mary Ann Lumsden; M Hassan Murad; JoAnn V Pinkerton; Richard J Santen
Journal:  J Clin Endocrinol Metab       Date:  2015-10-07       Impact factor: 5.958

10.  Sexual dysfunction and infertility as late effects of cancer treatment.

Authors:  Leslie R Schover; Marleen van der Kaaij; Eleonora van Dorst; Carien Creutzberg; Eric Huyghe; Cecilie E Kiserud
Journal:  EJC Suppl       Date:  2014-05-29
View more
  7 in total

1.  Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors.

Authors:  Allison M Quick; Andrew Hundley; Cynthia Evans; Julie A Stephens; Bhuvaneswari Ramaswamy; Raquel E Reinbolt; Anne M Noonan; Jeffrey Bryan Van Deusen; Robert Wesolowski; Daniel G Stover; Nicole Olivia Williams; Sagar D Sardesai; Stephanie S Faubion; Charles L Loprinzi; Maryam B Lustberg
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241

2.  Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lihu Gu; Wei Dai; Rongrong Fu; Hongfeng Lu; Jingyi Shen; Yetan Shi; Mengting Zhang; Ke Jiang; Feng Wu
Journal:  Front Oncol       Date:  2021-10-01       Impact factor: 6.244

Review 3.  Management of genitourinary syndrome of menopause in breast cancer survivors: An update.

Authors:  Daniel María Lubián López
Journal:  World J Clin Oncol       Date:  2022-02-24

Review 4.  New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review.

Authors:  Vittoria Benini; Alessandro Ferdinando Ruffolo; Arianna Casiraghi; Rebecca S Degliuomini; Matteo Frigerio; Andrea Braga; Maurizio Serati; Marco Torella; Massimo Candiani; Stefano Salvatore
Journal:  Medicina (Kaunas)       Date:  2022-06-06       Impact factor: 2.948

Review 5.  Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?

Authors:  Rossella E Nappi; Silvia Martella; Francesca Albani; Chiara Cassani; Ellis Martini; Fabio Landoni
Journal:  Healthcare (Basel)       Date:  2022-08-13

Review 6.  Dermatologic conditions in women receiving systemic cancer therapy.

Authors:  Michelle N Ferreira; Julie Y Ramseier; Jonathan S Leventhal
Journal:  Int J Womens Dermatol       Date:  2019-11-07

7.  Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study.

Authors:  Alexandra Moskalewicz; Amy Di Tomaso; Jacob J Kachura; Samantha Scime; Rosane Nisenbaum; Ronita Lee; Rashida Haq; Christine Derzko; Christine Brezden-Masley
Journal:  Curr Oncol       Date:  2022-03-09       Impact factor: 3.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.